Fagron is a pharmaceutical company specializing in the compounding of personalized medicine and sterile outsourcing services. The company provides a comprehensive range of products and services designed to enable pharmacists, prescribers, hospitals, and industry partners to deliver quality, safety, and service to patients. Its business segments include pharmaceutical compounding, sterile outsourcing, and the supply of excipients and equipment. Key products and brands include the Fagron Formulary, which offers customized formulas for various indications, and specific product lines such as DiluCap excipients, Pentravan, and Syrsend oral suspending vehicles. The company also manufactures and distributes compounding equipment under the FagronLab brand. Fagron serves customers globally, with operational presence in EMEA, North America, and Latin America. The company supports its clients through the Fagron Academy, a platform for medical scientific training and compounding courses, and an e-commerce shop for product distribution.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Medical Distribution Homepage fagron.com
Sector Healthcare IR page investors.fagron.com
Tags
pharmaceutical compounding, personalized medicine, sterile outsourcing, excipients, medical equipment, pharmacy services, global distribution, Fagron Formulary, DiluCap, Pentravan, SyrSpend, FagronLab, Fagron Academy, Fagron shop
Press page —

Metrics

Valuation  
Market cap € 1.812B
Market cap (USD) $ 1.987B
P/E 22.32
PEG 2.30
P/BV 3.57
P/S 2.08
P/OCF 16.49
P/FCF 26.22
Dividend yield —
Turnover / mcap —
Returns  
ROE 16.7%
ROI 11.1%
ROIC 14.3%
Profit margin 9.2%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) 9.7%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score —
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2024 FY 2023 FY 2022 FY 2021
Revenue 871.96M 762.991M 683.881M 573.808M
Net profit 80.554M 70.547M 69.612M 61.004M
Free cash flow 69.097M 86.159M 90.961M 57.688M

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Transparency notification Form TR-1 BE PART I

  1. Status of the notification Final

  2. Issuer Name FAGRON Identification number 0890-535-026

0

  1. Reason for the notification Acquisition or disposal of voting securities or voting rights

2

  1. Notification by

0

A parent undertaking or a controlling person

2

  1. Persons subject to the notification requirement 0 Address (for legal entities)

Name

1 George Street, Edinburgh, United Kingdom, EH2 2LL

Aberdeen Group plc

  1. Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Address (for legal entities)

Name

A

Please continue entering the information in part II concerning the persons referred to in Sections 5 and 6

Part II

  1. Date on which the threshold is crossed 14/10/2026 (DD/MM/YYYY)

  2. Threshold that is crossed (in %) 3 If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

  3. Denominator 73,817,024 Please enter the denominator before filling in the data

  4. Notified details A) Voting rights

After the transaction

Previous notification

of voting rights

Holders of voting rights

of voting rights

Linked to securities

% of voting rights

Not linked to the securities

Linked to securities

Not linked to the securities

S

0

0

0.00%

1

abrdn Investment Management Limited

1,850,845

1,603,022

2.17%

1

abrdn Investments Limited

344,558

779,439

1.06%

1

2,195,403

2,382,461

S

Aberdeen Group plc

Subtotal TOTAL

2,382,461

3.23% 0

3.23%

Start with "groups" of holders. Add subtotals with S , and then finish with the persons who are "alone". For groups, start with the ultimate controlling natural person or legal entity. The totals, subtotals and % will be updated once you have clicked on <CALCULATE>.

0.00%

After the transaction

B) Equivalent financial instruments

Holders of equivalent financial instruments

Exercise period or Expiration date date

Type of financial instrument

of voting rights

that may be acquired if the % of voting rights instrument is exercised

Settlement

0

TOTAL

0.00%

The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)

of voting rights % of voting rights

CALCULATE

2,382,461

3.23%

  1. Full chain of controlled undertakings through which the holding is effectively held, if applicable

Aberdeen Group plc is the parent company of the underlying intermediate holding company abrdn Investments (Holdings) Limited, which in turn is the holding company of the underlying investment management entity abrdn Investment Management Limited. Aberdeen Group plc is the parent company of the underlying intermediate holding company abrdn Holdings Limited, which in turn is the holding company of the underlying investment management entity abrdn Investments Limited. Aberdeen Group plc is not a controlled entity

  1. In case of proxy voting for only one GM (DD/MM/YYYY)

Holder

will cease to hold / will hold again

0

voting rights as of

  1. Additional information In reference to section 10, the shares detailed are managed by the named discretionary investment management entity within multiple portfolios on behalf of underlying clients, based on investment management agreements whereby the client has delegated the exercise of the voting power to the referenced investment manager. This disclosure is to reflect that the aggregate of Aberdeen Group plc affiliated investment management entities on behalf of multiple managed portfolios crossed above the 3% notifiable threshold on 14 October 2026 due to an in-specie transfer.

Done at Edinburgh

On

16/10/2026 (DD/MM/YYYY)

Name & capacity Chris Cole, Senior Major Shareholding Reporting Analyst

Signature

For security reasons, the unsigned form in xlsx format should be transmitted to [email protected]. You can do this manually OR if you have MS Outlook at your disposal via the “Save & Send” button. In addition, a signed copy in PDF format should also be transmitted.

News 22 Oct 2026 2 min read

Regulated information
Nazareth (Belgium)/Rotterdam (The Netherlands), 22 October 2026 – 6 PM CET

Disclosure of a transparency notification from Aberdeen Group plc

Pursuant to the Belgian act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received a transparency notification from Aberdeen Group plc, dated 16 October 2026.

Notification from Aberdeen Group plc

  • On 19 October 2026, Fagron received a transparency notification from Aberdeen Group plc informing the Company that its shareholding has crossed the 3% disclosure threshold upwards, following the acquisition of voting securities or voting rights attached to shares in Fagron.
  • The notification was submitted by ‘a parent undertaking or a controlling person’.
  • According to the notification, as of 14 October 2026, Aberdeen Group plc holds a total of 2,382,461 voting rights attached to shares in Fagron, consisting of:
    • 1,603,022 shares held through abrdn Investment Management Limited and;
    • 779,439 shares held through abrdn Investments Limited;

The total number of 2,382,461 shares corresponds to the same number of voting rights.

  • According to the notification, Aberdeen Group plc is the parent company of the underlying intermediate holding companies disclosed above.
  • Based on the total number of outstanding voting rights (73,817,024 as the applicable denominator), this shareholding of 2,382,461 voting rights held by Aberdeen Group plc represents 3.23% of the total voting rights.
  • The full transparency notification from Aberdeen Group plc is available on the Fagron website via the link .

Further information
Ignacio Artola
Global Head of Investor Relations
[email protected]

About Fagron

Fagron is the leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 40 countries around the world.

The Belgian company Fagron NV is based in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed through the Dutch company Fagron BV with head office in Rotterdam. 

Important information regarding forward-looking statements

Certain statements in this press release may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Consequently, Fagron cannot provide any guarantee that such forward-looking statements will, in fact, materialize and cannot accept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

News 16 Oct 2026 3 min read

Regulated information
Nazareth (Belgium)/Rotterdam (The Netherlands), 16 October 2026 – 6 PM CET

Disclosure of a transparency notification from BlackRock, Inc.

Pursuant to the Belgian act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received a transparency notification from BlackRock, Inc., dated 13 October 2026.

Notification from BlackRock, Inc.

  • On 14 October 2026, Fagron received a transparency notification from BlackRock, Inc. informing the Company that its shareholding has crossed the 3% disclosure threshold downwards, following the disposal of voting securities or voting rights attached to shares in Fagron, and despite the acquisition of equivalent financial instruments that are treated as voting securities.
  • The notification was submitted by ‘a parent undertaking or a controlling person’.
  • According to the notification, as of 12 October 2026, BlackRock, Inc. holds:
    • A total of 2,015,779 voting rights attached to shares in Fagron, consisting of:
      • 73,299 shares held through BlackRock Advisors (UK) Limited;
      • 41,249 shares held through BlackRock Asset Management Canada Limited;
      • 53 shares held through BlackRock Financial Management, Inc.;
      • 1,173,769 shares held by BlackRock Fund Advisors;
      • 669,283 shares held by BlackRock Institutional Trust Company, National Association;
      • 193 shares held by BlackRock Investment Management (Australia) Limited;
      • 39,191 shares held by BlackRock Investment Management (UK) Limited and;
      • 16,157 shares held by BlackRock Investment Management, LLC;
      • 2,585 shares held by Aperio Group, LLC.

The total number of 2,015,779 shares corresponds to the same number of voting rights.

  • A total of 166,184 equivalent financial instruments (Securities Lent and Contracts for Difference) in Fagron, consisting of:
    • 102,094 contracts held by BlackRock Advisors (UK) Limited;
    • 22,601 contracts held by BlackRock Advisors, LLC;
    • 31,403 contracts held by BlackRock Financial Management, Inc;
    • 5,875 contracts held by BlackRock Institutional Trust Company, National Association, and;
    • 4,211 contracts held by BlackRock Investment Management (UK) Limited.

The total number of 166,184 equivalent financial instruments corresponds to the same number of voting rights.

  • According to the notification, BlackRock, Inc. is the parent company of the underlying intermediate holding companies disclosed above.
  • Based on the total number of outstanding voting rights (73,817,024 as the applicable denominator), this shareholding of 2,181,963 voting rights held by BlackRock, Inc. represents 2.96% of the total voting rights.
  • The full transparency notifications from BlackRock, Inc. are available on the Fagron website via the link .

Further information
Ignacio Artola
Global Head of Investor Relations
[email protected]

About Fagron

Fagron is the leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 38 countries around the world.

The Belgian company Fagron NV is based in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed through the Dutch company Fagron BV with head office in Rotterdam.

Important information regarding forward-looking statements

Certain statements in this press release may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Consequently, Fagron cannot provide any guarantee that such forward-looking statements will, in fact, materialize and cannot accept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Prompts

Fagron NV (ticker FAGR), listed in Belgium.

ETFs Holding Fagron NV

ETF Weight in ETF Shares Market value As of
ASCI 3.24% 94,866 $ 2.538M Jul 31, 2026
AVDS 0.11% 15,186 $ 404.407K Nov 16, 2026
DFIS 0.05% 98,592 $ 2.64M Nov 12, 2026
DXIV 0.03% 2,843 $ 76.138K Nov 12, 2026
AVSD 0.02% 3,276 $ 87.241K Nov 16, 2026
DFSI 0.02% 8,454 $ 226.406K Nov 12, 2026
DFIC 0.02% 99,705 $ 2.67M Nov 12, 2026
DFAX 0.01% 56,510 $ 1.513M Nov 12, 2026
AVDE 0.01% 52,953 $ 1.41M Nov 16, 2026
DFAI 0.01% 62,745 $ 1.68M Nov 12, 2026